Glaukos Corporation (GKOS)
- Previous Close
110.41 - Open
110.84 - Bid 109.71 x 900
- Ask 109.96 x 1000
- Day's Range
107.41 - 110.84 - 52 Week Range
54.38 - 113.97 - Volume
453,818 - Avg. Volume
515,114 - Market Cap (intraday)
5.53B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-2.88 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
112.73
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
www.glaukos.comRecent News: GKOS
Performance Overview: GKOS
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GKOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GKOS
Valuation Measures
Market Cap
5.53B
Enterprise Value
5.64B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.43
Price/Book (mrq)
12.27
Enterprise Value/Revenue
17.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-43.15%
Return on Assets (ttm)
-7.95%
Return on Equity (ttm)
-29.37%
Revenue (ttm)
326.43M
Net Income Avi to Common (ttm)
-140.87M
Diluted EPS (ttm)
-2.88
Balance Sheet and Cash Flow
Total Cash (mrq)
272.86M
Total Debt/Equity (mrq)
85.58%
Levered Free Cash Flow (ttm)
-22.79M
Research Analysis: GKOS
Company Insights: GKOS
GKOS does not have Company Insights